Education
About Us
Working with TipRanks
Follow Us
Nabriva Therapeutics (NBRVF)
OTHER OTC:NBRVF
Total Valuation
Nabriva Therapeutics has a market cap or net worth of $323.00. The enterprise value is -$51.24M.
Market Cap$323.00
Enterprise Value-$51.24M
Share Statistics
Nabriva Therapeutics has 3,230,837 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,230,837
Owned by Insiders―
Owned by Institutions<0.01%
Financial Efficiency
Nabriva Therapeutics’s return on equity (ROE) is -17.37 and return on invested capital (ROIC) is -634.43%.
Return on Equity (ROE)-17.37
Return on Assets (ROA)-1.80
Return on Invested Capital (ROIC)-634.43%
Return on Capital Employed (ROCE)-13.34
Revenue Per Employee914.56K
Profits Per Employee-1.47M
Employee Count39
Asset Turnover1.12
Inventory Turnover2.95
Valuation Ratios
The current PE Ratio of Nabriva Therapeutics is -0.04. Nabriva Therapeutics’s PEG ratio is <0.01.
PE Ratio-0.04
PS Ratio0.00
PB Ratio0.77
Price to Fair Value0.77
Price to FCF-0.07
Price to Operating Cash Flow-0.07
PEG Ratio<0.01
Income Statement
In the last 12 months, Nabriva Therapeutics had revenue of 35.67M and earned -57.19M in profits. Earnings per share was -21.32.
Revenue35.67M
Gross Profit7.09M
Operating Income-55.49M
Pretax Income-55.62M
Net Income-57.19M
EBITDA-54.70M
Earnings Per Share (EPS)-21.32
Cash Flow
In the last 12 months, operating cash flow was -12.91M and capital expenditures -115.00K, giving a free cash flow of -13.02M billion.
Operating Cash Flow-12.91M
Free Cash Flow-13.02M
Free Cash Flow per Share-4.03
Dividends & Yields
Nabriva Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta120.89
52-Week Price Change0.00%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)591.00
Important Dates
Nabriva Therapeutics upcoming earnings date is Nov 9, 2023, TBA Not Confirmed.
Last Earnings DateAug 10, 2023
Next Earnings DateNov 9, 2023
Ex-Dividend Date―
Financial Position
Nabriva Therapeutics as a current ratio of 1.13, with Debt / Equity ratio of 158.55%
Current Ratio1.13
Quick Ratio0.78
Debt to Market Cap2.05
Net Debt to EBITDA0.13
Interest Coverage Ratio-79.50
Taxes
In the past 12 months, Nabriva Therapeutics has paid 1.57M in taxes.
Income Tax1.57M
Effective Tax Rate-0.03
Enterprise Valuation
Nabriva Therapeutics EV to EBITDA ratio is 0.08, with an EV/FCF ratio of 0.13.
EV to Sales-0.13
EV to EBITDA0.08
EV to Free Cash Flow0.13
EV to Operating Cash Flow0.13
Balance Sheet
Nabriva Therapeutics has $2.18M in cash and marketable securities with $540.00K in debt, giving a net cash position of -$1.64M billion.
Cash & Marketable Securities$2.18M
Total Debt$540.00K
Net Cash-$1.64M
Net Cash Per Share-$0.51
Tangible Book Value Per Share$1.23
Margins
Gross margin is 19.87%, with operating margin of -155.57%, and net profit margin of -160.33%.
Gross Margin19.87%
Operating Margin-155.57%
Pretax Margin-155.93%
Net Profit Margin-160.33%
EBITDA Margin-153.36%
EBIT Margin-153.97%
Analyst Forecast
The average price target for Nabriva Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―